,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2008', 'fs': 'Sep 2008', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079xyuUAA'}, 'Id': 'a0P2P0000079xyuUAA', 'Event_Date__c': '2008-09-05', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2008', 'Status_History__c': 'a132P000000ApLmQAK'}, 'change': None}]",Sep 2008,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2008', 'fs': 'Sep 2008', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079xyvUAA'}, 'Id': 'a0P2P0000079xyvUAA', 'Event_Date__c': '2008-09-06', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2008', 'Status_History__c': 'a132P000000ApLnQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2008', 'fs': 'Nov 2008', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2008.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2008.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3CUAQ'}, 'Id': 'a0P2P0000079y3CUAQ', 'Event_Date__c': '2008-11-06', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2008.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2008', 'Status_History__c': 'a132P000000ApMXQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2009', 'fs': 'Mar 2009', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3DUAQ'}, 'Id': 'a0P2P0000079y3DUAQ', 'Event_Date__c': '2009-03-01', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2009', 'Status_History__c': 'a132P000000ApOsQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2009', 'fs': 'Mar 2009', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3EUAQ'}, 'Id': 'a0P2P0000079y3EUAQ', 'Event_Date__c': '2009-03-10', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2009', 'Status_History__c': 'a132P000000ApP2QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2009', 'fs': 'May 2009', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3FUAQ'}, 'Id': 'a0P2P0000079y3FUAQ', 'Event_Date__c': '2009-05-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Formatted_Date__c': 'May 2009', 'Status_History__c': 'a132P000000ApQsQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-analgesic-subcommittee-minutes-2018-03.pdf"" target=""_blank"">Analgesic Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-analgesic-subcommittee-minutes-2018-03.pdf"" target=""_blank"">Analgesic Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2018', 'fs': 'Mar 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Analgesic Subcommittee at meeting Tuesday 27 March 2018.', 'fs': 'Clinical advice received from Analgesic Subcommittee at meeting Tuesday 27 March 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3MUAQ'}, 'Id': 'a0P2P0000079y3MUAQ', 'Event_Date__c': '2018-03-27', 'Event_Description__c': 'Clinical advice received from Analgesic Subcommittee at meeting Tuesday 27 March 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-analgesic-subcommittee-minutes-2018-03.pdf"" target=""_blank"">Analgesic Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Mar 2018', 'Status_History__c': 'a132P000000ArRNQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3NUAQ'}, 'Id': 'a0P2P0000079y3NUAQ', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVRQA0'}, 'change': None}, {'Summary': {'s': 'Correspondence from NZSA In-patient Pain Network', 'fs': 'Correspondence from NZSA In-patient Pain Network', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2019', 'fs': 'Mar 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3PUAQ'}, 'Id': 'a0P2P0000079y3PUAQ', 'Event_Date__c': '2019-03-07', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'Correspondence from NZSA In-patient Pain Network', 'Formatted_Date__c': 'Mar 2019', 'Status_History__c': 'a132P000000Ard6QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Committee recommended that the application for buprenorphine transdermal\xa0patches for persistent moderate/severe chronic non-malignant pain be declined, based\xa0on insufficient evidence of long-term analgesic benefit, lack of evidence regarding\xa0functional improvements and improvements in health-related quality of life, and concerns\xa0regarding diversion and possible societal harm.\xa0</p><p><br></p><p>The Committee recommended that PHARMAC staff consider a review of the funding of\xa0and access to opioid analgesics for chronic non-malignant pain in New Zealand and\xa0bring a discussion paper to PTAC on this matter at a future meeting.\xa0</p>', 'fs': '<p>The Committee recommended that the application for buprenorphine transdermal\xa0patches for persistent moderate/severe chronic non-malignant pain be declined, based\xa0on insufficient evidence of long-term analgesic benefit, lack of evidence regarding\xa0functional improvements and improvements in health-related quality of life, and concerns\xa0regarding diversion and possible societal harm.\xa0</p><p><br></p><p>The Committee recommended that PHARMAC staff consider a review of the funding of\xa0and access to opioid analgesics for chronic non-malignant pain in New Zealand and\xa0bring a discussion paper to PTAC on this matter at a future meeting.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Committee reviewed correspondence from the New Zealand Society of\xa0Anaesthetists Inpatient Pain Network requesting that PHARMAC reconsider the\xa0recommendation of PTAC that funding for buprenorphine transdermal patches be\xa0declined.\xa0</p><p><br></p><p>The Committee noted the correspondent had suggested that access to buprenorphine\xa0transdermal patches be limited to certain prescribers (anaesthetists, pain physicians and\xa0palliative care specialists) and the following patient groups;\xa0</p><ul><li>Patients with difficult to control pain\xa0</li><li>Elderly patients with co-morbidities\xa0</li><li>Trauma patients with concurrent substance misuse\xa0</li><li>Patients requiring transitional analgesia\xa0</li></ul><p><br></p><p>The Committee reviewed the history of prescribing opioids for use in chronic non-malignant pain, along with trends in opioid prescribing practice internationally and in New\xa0Zealand. The Committee noted <a href=""https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/opioids/"" target=""_blank"">data released by the Health Quality and Safety\xa0Commission</a> and considered there was a concerning trend in the use of strong opioids,\xa0in particular the use of morphine and fentanyl patches in rest homes.\xa0\xa0</p><p><br></p><p>The Committee noted that it had reviewed an application for buprenorphine transdermal\xa0patches in 2009 and, based on the evidence at that time, recommended that\xa0buprenorphine patches be funded with a low priority. The Committee noted that in late\xa02017, the supplier of buprenorphine patches submitted an updated commercial proposal\xa0to PHARMAC. The Committee noted that PHARMAC staff sought the advice of the\xa0Analgesic Subcommittee at its March 2018 meeting on the likely benefits and risks of\xa0buprenorphine as an analgesic agent in the setting of chronic non-malignant pain, the\xa0benefits and suitability of a weekly buprenorphine patch, and the likely place in therapy.\xa0\xa0</p><p><br></p><p>\xa0The Committee noted that the Analgesic Subcommittee recommended that the\xa0application for buprenorphine patches for the treatment of severe chronic non-cancer\xa0pain be declined. The Committee noted that at its March 2018 meeting the Analgesic\xa0Subcommittee considered that PHARMAC should carefully consider the potential\xa0consequences of abuse, misuse, and dependence in its funding assessments of new\xa0opioid medicines, as any new funding would likely increase the total opioid market and\xa0the number of patients being treated with an opioid.\xa0</p><p><br></p><p>The Committee reviewed the pharmacology of buprenorphine. The Committee noted\xa0that patches are designed to provide a steady delivery of buprenorphine for up to 7 days\xa0up to a maximum dose delivery of 40 micrograms per hour. The Committee noted that\xa0plasma steady state concentrations are reached at day 3 of treatment and therefore\xa0considered that the patch would not be suitable for the management of acute pain. The\xa0Committee noted that there was no dose adjustment needed in renal impairment or in\xa0mild-moderate hepatic impairment.\xa0\xa0</p><p><br></p><p>The Committee considered there were a number of potentially beneficial differences in\xa0comparison to other opioid medications, including a ceiling effect on respiratory\xa0depression, no adverse effects on the hypothalamic-pituitary-adrenal axis, no induction\xa0of hypogonadism, and no clinically significant impact on QTc interval. The Committee\xa0considered, however, that much of the safety data came from animal studies and studies\xa0in healthy volunteers, rather than in the target population (ie. patients with chronic non-malignant pain).\xa0</p><p><br></p><p>The Committee noted literature provided by the correspondent, and considered in\xa0particular the following evidence regarding efficacy;\xa0</p><p><br></p><ul><li>The Committee considered a systematic review of buprenorphine that included 15\xa0trials of buprenorphine transdermal patches (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29239947"" target=""_blank"">Aiyer et al. Anaesth Analg\xa02018;127:529-38</a>). The Committee noted that there were 10 positive trials,\xa0however only 1 trial demonstrated superiority over an active comparator. The\xa0Committee considered that there were a number of different formulations of\xa0buprenorphine studied, in a number of different chronic pain conditions, and that\xa0the populations were therefore heterogeneous in nature. The Committee\xa0considered that due to the variety of endpoints used and population heterogeneity\xa0a formal meta-analysis was not possible. The Committee considered an\xa0accompanying editorial (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30028385"" target=""_blank"">Sun et al. Anesth Analg 2018;127:336-7</a>), which\xa0commented that the use of buprenorphine in chronic pain has significant\xa0implications in peri-operative analgesia as its partial agonist activity may cause\xa0reduced efficacy of other strong opioids\xa0\xa0</li></ul><p><br></p><ul><li>The Committee considered a meta-analysis of 28 randomised controlled trials\xa0comparing buprenorphine with morphine and noted that none of these studies\xa0used a transdermal presentation of buprenorphine and therefore considered that\xa0the analysis was not relevant to the application (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29576108"" target=""_blank"">White et al Br J Anaesth\xa02018;120:668-78</a>).\xa0</li></ul><p><br></p><ul><li>The Committee considered a randomised controlled trial investigating the\xa0comparative efficacy of transdermal buprenorphine and slow-release tramadol in\xa0the postoperative setting following single-level spinal fusion surgery (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28730328"" target=""_blank"">Kim et al Eur\xa0Spine J 2017;26:2961-8</a>). The Committee considered the rationale for the use of\xa0transdermal buprenorphine in this patient cohort was unclear, as the majority of\xa0patients were unlikely to require transdermal buprenorphine for the duration\xa0prescribed in the study.\xa0</li></ul><p><br></p><ul><li>The Committee considered a randomised controlled trial investigating the efficacy\xa0of transdermal buprenorphine in neuropathic pain in comparison to placebo. The\xa0Committee considered that the treatment effect reported in this study (30%\xa0reduction in average versus baseline pain at week 12) was modest and unlikely to\xa0be clinically significant (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27311495"" target=""_blank"">Simpson et al. Diabetes Care 2016;39:1493-500</a>).\xa0</li></ul><p><br></p><p>The Committee considered literature provided by the correspondent, regarding safety of\xa0buprenorphine patches, including the following:\xa0</p><p><br></p><ul><li>The Committee considered a literature review (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22809652"" target=""_blank"">Davis MP. J Support Oncol\xa02012;10:209-19</a>) of buprenorphine transdermal patches. The authors of the review\xa0reported that a ceiling effect was observed for respiratory depression. The\xa0Committee considered that the evidence to support this was from studies in\xa0animals and healthy volunteers and therefore would not necessarily be\xa0representative of patients with chronic non-cancer pain, particularly those taking\xa0other central nervous system depressants. The Committee considered that many\xa0patients with chronic non-cancer pain may be using other central nervous system\xa0depressants such as benzodiazepines, and this concomitant use could\xa0significantly increase the risk of respiratory depression.\xa0\xa0</li></ul><p><br></p><ul><li>The Committee considered a retrospective analysis of 16 placebo-controlled and\xa0active-controlled, and uncontrolled studies that compared safety profiles of\xa0buprenorphine transdermal patches in older patients (≥ 65 years) with younger\xa0patients (&lt; 65 years) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27929709"" target=""_blank"">Pergolizzi et al. Postgrad Med 2017;129:92-101</a>). The\xa0Committee considered that the data indicated that older patients were more likely\xa0than younger patients to experience adverse events associated with\xa0buprenorphine transdermal patches. The Committee considered that there would\xa0be value in comparative analysis of the safety of buprenorphine transdermal\xa0patches in older versus younger patients relative to other strong opioids, however\xa0the analysis presented was limited by the relatively small patient numbers.\xa0</li></ul><p><br></p><ul><li>The Committee considered a retrospective cohort study comparing rates of abuse,\xa0suspected suicidal intent and fatalities with buprenorphine transdermal patches in\xa0comparison to other opioid analgesics using data from the National Poison Data\xa0System in the US (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27922764"" target=""_blank"">Coplan PM et al. Postgrad Med 2017;129:55-61</a>). The\xa0Committee considered that the study was limited by the relatively low patient\xa0numbers prescribed buprenorphine versus other strong opioids. The Committee\xa0considered that using Poison Centre reporting may have led to under-reporting of\xa0events, and therefore considered caution was needed in interpreting the\xa0conclusion that there are lower rates of these events with buprenorphine\xa0transdermal patches in comparison to other opioid analgesics. In addition, the\xa0Committee considered that the majority of patients dispensed buprenorphine\xa0transdermal patches in the Poison Centre database used the patch concomitantly\xa0with other opioids and therefore that the use of the patch did not mean that patients\xa0would reduce their use of other opioids.\xa0</li></ul><p><br></p><ul><li>The Committee considered another retrospective cohort study from the National\xa0Poison Data System in the US evaluating buprenorphine exposure in children and\xa0adolescents (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29941678"" target=""_blank"">Post S et al. Pediatrics 2018;142:e20173562</a>). The Committee\xa0considered that this analysis included other buprenorphine formulations in addition\xa0to the transdermal patch. The Committee considered that this analysis suggested\xa0a small risk of intentional and unintentional exposure in children and adolescents\xa0that would be of potential concern if buprenorphine transdermal patches were\xa0made available in New Zealand.\xa0</li></ul><p><br></p><ul><li>The Committee considered a <a href=""https://www.cadth.ca/buprenorphine-chronic-pain-review-clinical-effectiveness-0"" target=""_blank"">rapid response document</a> prepared by the Canadian\xa0Agency for Drugs and Technology in Health (CADTH) in January 2017 that\xa0provided a summary and critical appraisal of the evidence for the clinical\xa0effectiveness of buprenorphine in chronic non-cancer pain. The Committee\xa0considered the conclusion of this review was that the improvements in pain for\xa0patients with chronic non-cancer pain, from treatment with buprenorphine relative\xa0to placebo, was modest and in some studies did not meet the recognised standard\xa0for minimum clinically important significance. The Committee considered that the\xa0authors concluded that available evidence was insufficient to assess the relative\xa0harms of buprenorphine to other opioids in patients with chronic non-cancer pain,\xa0including in relation to respiratory depression.\xa0</li></ul><p><br></p><p>The Committee considered that the evidence reviewed did not change its view that there\xa0is limited evidence of long-term analgesic benefit and functional improvements for the\xa0use of opioids, including buprenorphine transdermal patches, in the management of\xa0chronic non-malignant pain. The Committee considered that there is overwhelming\xa0evidence to suggest possible harms resulting from long term opioid use. The Committee\xa0considered that non-opioid pharmacological therapy and non-pharmacological therapies\xa0are the preferred treatment options for chronic non-malignant pain to improve functional\xa0status and health-related quality of life.\xa0\xa0</p><p><br></p><p>The Committee considered that the evidence it reviewed did not change its view that\xa0buprenorphine has a moderate abuse potential and that should buprenorphine patches\xa0be funded, there would likely be a proportion of use that would be inappropriate,\xa0including diversion and potential societal harm. The Committee considered that limiting\xa0</p><p>prescribing to certain prescriber types and patient groups would be unlikely to\xa0significantly attenuate this risk. The Committee also considered that despite\xa0buprenorphine being a transdermal patch it was possible to extract the buprenorphine\xa0from the patch.\xa0</p><p><br></p><p>The Committee considered that if buprenorphine transdermal patches were to be\xa0funded, specific advice should be sought from the Analgesic Subcommittee regarding\xa0appropriate Special Authority criteria, and that prescribing should be limited to Pain\xa0Medicine Specialists and Addiction Medicine Specialists.\xa0</p><p><br></p><p>The Committee considered that the evidence and information provided by the New\xa0Zealand Society of Anaesthetists Inpatient Pain Network did not change its view on the\xa0Analgesic Subcommittee’s recommendation that funding for buprenorphine transdermal\xa0patches be declined.\xa0</p><p><br></p><p>The Committee considered the current opioid epidemic in the US and Canada and the\xa0increasing problem of opioid prescribing for chronic non-malignant pain in New Zealand,\xa0despite large educational campaigns. The Committee considered that one possible way\xa0of reducing inappropriate prescribing of opioids for chronic non-malignant pain would be\xa0to consider funding and/or access restrictions on strong opioids. The Committee\xa0considered that similar considerations had been given to creating funding restrictions for\xa0antibiotics to help reduce antimicrobial resistance; however practically this had been\xa0difficult to implement due to significant regional variations in prescribing practice.\xa0</p>', 'fs': '<p>The Committee reviewed correspondence from the New Zealand Society of\xa0Anaesthetists Inpatient Pain Network requesting that PHARMAC reconsider the\xa0recommendation of PTAC that funding for buprenorphine transdermal patches be\xa0declined.\xa0</p><p><br></p><p>The Committee noted the correspondent had suggested that access to buprenorphine\xa0transdermal patches be limited to certain prescribers (anaesthetists, pain physicians and\xa0palliative care specialists) and the following patient groups;\xa0</p><ul><li>Patients with difficult to control pain\xa0</li><li>Elderly patients with co-morbidities\xa0</li><li>Trauma patients with concurrent substance misuse\xa0</li><li>Patients requiring transitional analgesia\xa0</li></ul><p><br></p><p>The Committee reviewed the history of prescribing opioids for use in chronic non-malignant pain, along with trends in opioid prescribing practice internationally and in New\xa0Zealand. The Committee noted <a href=""https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/opioids/"" target=""_blank"">data released by the Health Quality and Safety\xa0Commission</a> and considered there was a concerning trend in the use of strong opioids,\xa0in particular the use of morphine and fentanyl patches in rest homes.\xa0\xa0</p><p><br></p><p>The Committee noted that it had reviewed an application for buprenorphine transdermal\xa0patches in 2009 and, based on the evidence at that time, recommended that\xa0buprenorphine patches be funded with a low priority. The Committee noted that in late\xa02017, the supplier of buprenorphine patches submitted an updated commercial proposal\xa0to PHARMAC. The Committee noted that PHARMAC staff sought the advice of the\xa0Analgesic Subcommittee at its March 2018 meeting on the likely benefits and risks of\xa0buprenorphine as an analgesic agent in the setting of chronic non-malignant pain, the\xa0benefits and suitability of a weekly buprenorphine patch, and the likely place in therapy.\xa0\xa0</p><p><br></p><p>\xa0The Committee noted that the Analgesic Subcommittee recommended that the\xa0application for buprenorphine patches for the treatment of severe chronic non-cancer\xa0pain be declined. The Committee noted that at its March 2018 meeting the Analgesic\xa0Subcommittee considered that PHARMAC should carefully consider the potential\xa0consequences of abuse, misuse, and dependence in its funding assessments of new\xa0opioid medicines, as any new funding would likely increase the total opioid market and\xa0the number of patients being treated with an opioid.\xa0</p><p><br></p><p>The Committee reviewed the pharmacology of buprenorphine. The Committee noted\xa0that patches are designed to provide a steady delivery of buprenorphine for up to 7 days\xa0up to a maximum dose delivery of 40 micrograms per hour. The Committee noted that\xa0plasma steady state concentrations are reached at day 3 of treatment and therefore\xa0considered that the patch would not be suitable for the management of acute pain. The\xa0Committee noted that there was no dose adjustment needed in renal impairment or in\xa0mild-moderate hepatic impairment.\xa0\xa0</p><p><br></p><p>The Committee considered there were a number of potentially beneficial differences in\xa0comparison to other opioid medications, including a ceiling effect on respiratory\xa0depression, no adverse effects on the hypothalamic-pituitary-adrenal axis, no induction\xa0of hypogonadism, and no clinically significant impact on QTc interval. The Committee\xa0considered, however, that much of the safety data came from animal studies and studies\xa0in healthy volunteers, rather than in the target population (ie. patients with chronic non-malignant pain).\xa0</p><p><br></p><p>The Committee noted literature provided by the correspondent, and considered in\xa0particular the following evidence regarding efficacy;\xa0</p><p><br></p><ul><li>The Committee considered a systematic review of buprenorphine that included 15\xa0trials of buprenorphine transdermal patches (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29239947"" target=""_blank"">Aiyer et al. Anaesth Analg\xa02018;127:529-38</a>). The Committee noted that there were 10 positive trials,\xa0however only 1 trial demonstrated superiority over an active comparator. The\xa0Committee considered that there were a number of different formulations of\xa0buprenorphine studied, in a number of different chronic pain conditions, and that\xa0the populations were therefore heterogeneous in nature. The Committee\xa0considered that due to the variety of endpoints used and population heterogeneity\xa0a formal meta-analysis was not possible. The Committee considered an\xa0accompanying editorial (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30028385"" target=""_blank"">Sun et al. Anesth Analg 2018;127:336-7</a>), which\xa0commented that the use of buprenorphine in chronic pain has significant\xa0implications in peri-operative analgesia as its partial agonist activity may cause\xa0reduced efficacy of other strong opioids\xa0\xa0</li></ul><p><br></p><ul><li>The Committee considered a meta-analysis of 28 randomised controlled trials\xa0comparing buprenorphine with morphine and noted that none of these studies\xa0used a transdermal presentation of buprenorphine and therefore considered that\xa0the analysis was not relevant to the application (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29576108"" target=""_blank"">White et al Br J Anaesth\xa02018;120:668-78</a>).\xa0</li></ul><p><br></p><ul><li>The Committee considered a randomised controlled trial investigating the\xa0comparative efficacy of transdermal buprenorphine and slow-release tramadol in\xa0the postoperative setting following single-level spinal fusion surgery (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28730328"" target=""_blank"">Kim et al Eur\xa0Spine J 2017;26:2961-8</a>). The Committee considered the rationale for the use of\xa0transdermal buprenorphine in this patient cohort was unclear, as the majority of\xa0patients were unlikely to require transdermal buprenorphine for the duration\xa0prescribed in the study.\xa0</li></ul><p><br></p><ul><li>The Committee considered a randomised controlled trial investigating the efficacy\xa0of transdermal buprenorphine in neuropathic pain in comparison to placebo. The\xa0Committee considered that the treatment effect reported in this study (30%\xa0reduction in average versus baseline pain at week 12) was modest and unlikely to\xa0be clinically significant (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27311495"" target=""_blank"">Simpson et al. Diabetes Care 2016;39:1493-500</a>).\xa0</li></ul><p><br></p><p>The Committee considered literature provided by the correspondent, regarding safety of\xa0buprenorphine patches, including the following:\xa0</p><p><br></p><ul><li>The Committee considered a literature review (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22809652"" target=""_blank"">Davis MP. J Support Oncol\xa02012;10:209-19</a>) of buprenorphine transdermal patches. The authors of the review\xa0reported that a ceiling effect was observed for respiratory depression. The\xa0Committee considered that the evidence to support this was from studies in\xa0animals and healthy volunteers and therefore would not necessarily be\xa0representative of patients with chronic non-cancer pain, particularly those taking\xa0other central nervous system depressants. The Committee considered that many\xa0patients with chronic non-cancer pain may be using other central nervous system\xa0depressants such as benzodiazepines, and this concomitant use could\xa0significantly increase the risk of respiratory depression.\xa0\xa0</li></ul><p><br></p><ul><li>The Committee considered a retrospective analysis of 16 placebo-controlled and\xa0active-controlled, and uncontrolled studies that compared safety profiles of\xa0buprenorphine transdermal patches in older patients (≥ 65 years) with younger\xa0patients (&lt; 65 years) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27929709"" target=""_blank"">Pergolizzi et al. Postgrad Med 2017;129:92-101</a>). The\xa0Committee considered that the data indicated that older patients were more likely\xa0than younger patients to experience adverse events associated with\xa0buprenorphine transdermal patches. The Committee considered that there would\xa0be value in comparative analysis of the safety of buprenorphine transdermal\xa0patches in older versus younger patients relative to other strong opioids, however\xa0the analysis presented was limited by the relatively small patient numbers.\xa0</li></ul><p><br></p><ul><li>The Committee considered a retrospective cohort study comparing rates of abuse,\xa0suspected suicidal intent and fatalities with buprenorphine transdermal patches in\xa0comparison to other opioid analgesics using data from the National Poison Data\xa0System in the US (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27922764"" target=""_blank"">Coplan PM et al. Postgrad Med 2017;129:55-61</a>). The\xa0Committee considered that the study was limited by the relatively low patient\xa0numbers prescribed buprenorphine versus other strong opioids. The Committee\xa0considered that using Poison Centre reporting may have led to under-reporting of\xa0events, and therefore considered caution was needed in interpreting the\xa0conclusion that there are lower rates of these events with buprenorphine\xa0transdermal patches in comparison to other opioid analgesics. In addition, the\xa0Committee considered that the majority of patients dispensed buprenorphine\xa0transdermal patches in the Poison Centre database used the patch concomitantly\xa0with other opioids and therefore that the use of the patch did not mean that patients\xa0would reduce their use of other opioids.\xa0</li></ul><p><br></p><ul><li>The Committee considered another retrospective cohort study from the National\xa0Poison Data System in the US evaluating buprenorphine exposure in children and\xa0adolescents (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29941678"" target=""_blank"">Post S et al. Pediatrics 2018;142:e20173562</a>). The Committee\xa0considered that this analysis included other buprenorphine formulations in addition\xa0to the transdermal patch. The Committee considered that this analysis suggested\xa0a small risk of intentional and unintentional exposure in children and adolescents\xa0that would be of potential concern if buprenorphine transdermal patches were\xa0made available in New Zealand.\xa0</li></ul><p><br></p><ul><li>The Committee considered a <a href=""https://www.cadth.ca/buprenorphine-chronic-pain-review-clinical-effectiveness-0"" target=""_blank"">rapid response document</a> prepared by the Canadian\xa0Agency for Drugs and Technology in Health (CADTH) in January 2017 that\xa0provided a summary and critical appraisal of the evidence for the clinical\xa0effectiveness of buprenorphine in chronic non-cancer pain. The Committee\xa0considered the conclusion of this review was that the improvements in pain for\xa0patients with chronic non-cancer pain, from treatment with buprenorphine relative\xa0to placebo, was modest and in some studies did not meet the recognised standard\xa0for minimum clinically important significance. The Committee considered that the\xa0authors concluded that available evidence was insufficient to assess the relative\xa0harms of buprenorphine to other opioids in patients with chronic non-cancer pain,\xa0including in relation to respiratory depression.\xa0</li></ul><p><br></p><p>The Committee considered that the evidence reviewed did not change its view that there\xa0is limited evidence of long-term analgesic benefit and functional improvements for the\xa0use of opioids, including buprenorphine transdermal patches, in the management of\xa0chronic non-malignant pain. The Committee considered that there is overwhelming\xa0evidence to suggest possible harms resulting from long term opioid use. The Committee\xa0considered that non-opioid pharmacological therapy and non-pharmacological therapies\xa0are the preferred treatment options for chronic non-malignant pain to improve functional\xa0status and health-related quality of life.\xa0\xa0</p><p><br></p><p>The Committee considered that the evidence it reviewed did not change its view that\xa0buprenorphine has a moderate abuse potential and that should buprenorphine patches\xa0be funded, there would likely be a proportion of use that would be inappropriate,\xa0including diversion and potential societal harm. The Committee considered that limiting\xa0</p><p>prescribing to certain prescriber types and patient groups would be unlikely to\xa0significantly attenuate this risk. The Committee also considered that despite\xa0buprenorphine being a transdermal patch it was possible to extract the buprenorphine\xa0from the patch.\xa0</p><p><br></p><p>The Committee considered that if buprenorphine transdermal patches were to be\xa0funded, specific advice should be sought from the Analgesic Subcommittee regarding\xa0appropriate Special Authority criteria, and that prescribing should be limited to Pain\xa0Medicine Specialists and Addiction Medicine Specialists.\xa0</p><p><br></p><p>The Committee considered that the evidence and information provided by the New\xa0Zealand Society of Anaesthetists Inpatient Pain Network did not change its view on the\xa0Analgesic Subcommittee’s recommendation that funding for buprenorphine transdermal\xa0patches be declined.\xa0</p><p><br></p><p>The Committee considered the current opioid epidemic in the US and Canada and the\xa0increasing problem of opioid prescribing for chronic non-malignant pain in New Zealand,\xa0despite large educational campaigns. The Committee considered that one possible way\xa0of reducing inappropriate prescribing of opioids for chronic non-malignant pain would be\xa0to consider funding and/or access restrictions on strong opioids. The Committee\xa0considered that similar considerations had been given to creating funding restrictions for\xa0antibiotics to help reduce antimicrobial resistance; however practically this had been\xa0difficult to implement due to significant regional variations in prescribing practice.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>The Committee reviewed correspondence requesting reconsideration of an application\xa0for buprenorphine transdermal patches for the treatment of chronic moderate/severe\xa0non-malignant pain.\xa0\xa0</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0\xa0</p>', 'fs': '<p>The Committee reviewed correspondence requesting reconsideration of an application\xa0for buprenorphine transdermal patches for the treatment of chronic moderate/severe\xa0non-malignant pain.\xa0\xa0</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 23 May 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 23 May 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3QUAQ'}, 'Id': 'a0P2P0000079y3QUAQ', 'Event_Date__c': '2019-05-23', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 23 May 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'May 2019', 'Published_Recommendation__c': '<p>The Committee recommended that the application for buprenorphine transdermal\xa0patches for persistent moderate/severe chronic non-malignant pain be declined, based\xa0on insufficient evidence of long-term analgesic benefit, lack of evidence regarding\xa0functional improvements and improvements in health-related quality of life, and concerns\xa0regarding diversion and possible societal harm.\xa0</p><p><br></p><p>The Committee recommended that PHARMAC staff consider a review of the funding of\xa0and access to opioid analgesics for chronic non-malignant pain in New Zealand and\xa0bring a discussion paper to PTAC on this matter at a future meeting.\xa0</p>', 'Published_Application__c': '<p>The Committee reviewed correspondence requesting reconsideration of an application\xa0for buprenorphine transdermal patches for the treatment of chronic moderate/severe\xa0non-malignant pain.\xa0\xa0</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0\xa0</p>', 'Published_Discussion__c': '<p>The Committee reviewed correspondence from the New Zealand Society of\xa0Anaesthetists Inpatient Pain Network requesting that PHARMAC reconsider the\xa0recommendation of PTAC that funding for buprenorphine transdermal patches be\xa0declined.\xa0</p><p><br></p><p>The Committee noted the correspondent had suggested that access to buprenorphine\xa0transdermal patches be limited to certain prescribers (anaesthetists, pain physicians and\xa0palliative care specialists) and the following patient groups;\xa0</p><ul><li>Patients with difficult to control pain\xa0</li><li>Elderly patients with co-morbidities\xa0</li><li>Trauma patients with concurrent substance misuse\xa0</li><li>Patients requiring transitional analgesia\xa0</li></ul><p><br></p><p>The Committee reviewed the history of prescribing opioids for use in chronic non-malignant pain, along with trends in opioid prescribing practice internationally and in New\xa0Zealand. The Committee noted <a href=""https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/opioids/"" target=""_blank"">data released by the Health Quality and Safety\xa0Commission</a> and considered there was a concerning trend in the use of strong opioids,\xa0in particular the use of morphine and fentanyl patches in rest homes.\xa0\xa0</p><p><br></p><p>The Committee noted that it had reviewed an application for buprenorphine transdermal\xa0patches in 2009 and, based on the evidence at that time, recommended that\xa0buprenorphine patches be funded with a low priority. The Committee noted that in late\xa02017, the supplier of buprenorphine patches submitted an updated commercial proposal\xa0to PHARMAC. The Committee noted that PHARMAC staff sought the advice of the\xa0Analgesic Subcommittee at its March 2018 meeting on the likely benefits and risks of\xa0buprenorphine as an analgesic agent in the setting of chronic non-malignant pain, the\xa0benefits and suitability of a weekly buprenorphine patch, and the likely place in therapy.\xa0\xa0</p><p><br></p><p>\xa0The Committee noted that the Analgesic Subcommittee recommended that the\xa0application for buprenorphine patches for the treatment of severe chronic non-cancer\xa0pain be declined. The Committee noted that at its March 2018 meeting the Analgesic\xa0Subcommittee considered that PHARMAC should carefully consider the potential\xa0consequences of abuse, misuse, and dependence in its funding assessments of new\xa0opioid medicines, as any new funding would likely increase the total opioid market and\xa0the number of patients being treated with an opioid.\xa0</p><p><br></p><p>The Committee reviewed the pharmacology of buprenorphine. The Committee noted\xa0that patches are designed to provide a steady delivery of buprenorphine for up to 7 days\xa0up to a maximum dose delivery of 40 micrograms per hour. The Committee noted that\xa0plasma steady state concentrations are reached at day 3 of treatment and therefore\xa0considered that the patch would not be suitable for the management of acute pain. The\xa0Committee noted that there was no dose adjustment needed in renal impairment or in\xa0mild-moderate hepatic impairment.\xa0\xa0</p><p><br></p><p>The Committee considered there were a number of potentially beneficial differences in\xa0comparison to other opioid medications, including a ceiling effect on respiratory\xa0depression, no adverse effects on the hypothalamic-pituitary-adrenal axis, no induction\xa0of hypogonadism, and no clinically significant impact on QTc interval. The Committee\xa0considered, however, that much of the safety data came from animal studies and studies\xa0in healthy volunteers, rather than in the target population (ie. patients with chronic non-malignant pain).\xa0</p><p><br></p><p>The Committee noted literature provided by the correspondent, and considered in\xa0particular the following evidence regarding efficacy;\xa0</p><p><br></p><ul><li>The Committee considered a systematic review of buprenorphine that included 15\xa0trials of buprenorphine transdermal patches (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29239947"" target=""_blank"">Aiyer et al. Anaesth Analg\xa02018;127:529-38</a>). The Committee noted that there were 10 positive trials,\xa0however only 1 trial demonstrated superiority over an active comparator. The\xa0Committee considered that there were a number of different formulations of\xa0buprenorphine studied, in a number of different chronic pain conditions, and that\xa0the populations were therefore heterogeneous in nature. The Committee\xa0considered that due to the variety of endpoints used and population heterogeneity\xa0a formal meta-analysis was not possible. The Committee considered an\xa0accompanying editorial (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30028385"" target=""_blank"">Sun et al. Anesth Analg 2018;127:336-7</a>), which\xa0commented that the use of buprenorphine in chronic pain has significant\xa0implications in peri-operative analgesia as its partial agonist activity may cause\xa0reduced efficacy of other strong opioids\xa0\xa0</li></ul><p><br></p><ul><li>The Committee considered a meta-analysis of 28 randomised controlled trials\xa0comparing buprenorphine with morphine and noted that none of these studies\xa0used a transdermal presentation of buprenorphine and therefore considered that\xa0the analysis was not relevant to the application (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29576108"" target=""_blank"">White et al Br J Anaesth\xa02018;120:668-78</a>).\xa0</li></ul><p><br></p><ul><li>The Committee considered a randomised controlled trial investigating the\xa0comparative efficacy of transdermal buprenorphine and slow-release tramadol in\xa0the postoperative setting following single-level spinal fusion surgery (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28730328"" target=""_blank"">Kim et al Eur\xa0Spine J 2017;26:2961-8</a>). The Committee considered the rationale for the use of\xa0transdermal buprenorphine in this patient cohort was unclear, as the majority of\xa0patients were unlikely to require transdermal buprenorphine for the duration\xa0prescribed in the study.\xa0</li></ul><p><br></p><ul><li>The Committee considered a randomised controlled trial investigating the efficacy\xa0of transdermal buprenorphine in neuropathic pain in comparison to placebo. The\xa0Committee considered that the treatment effect reported in this study (30%\xa0reduction in average versus baseline pain at week 12) was modest and unlikely to\xa0be clinically significant (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27311495"" target=""_blank"">Simpson et al. Diabetes Care 2016;39:1493-500</a>).\xa0</li></ul><p><br></p><p>The Committee considered literature provided by the correspondent, regarding safety of\xa0buprenorphine patches, including the following:\xa0</p><p><br></p><ul><li>The Committee considered a literature review (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22809652"" target=""_blank"">Davis MP. J Support Oncol\xa02012;10:209-19</a>) of buprenorphine transdermal patches. The authors of the review\xa0reported that a ceiling effect was observed for respiratory depression. The\xa0Committee considered that the evidence to support this was from studies in\xa0animals and healthy volunteers and therefore would not necessarily be\xa0representative of patients with chronic non-cancer pain, particularly those taking\xa0other central nervous system depressants. The Committee considered that many\xa0patients with chronic non-cancer pain may be using other central nervous system\xa0depressants such as benzodiazepines, and this concomitant use could\xa0significantly increase the risk of respiratory depression.\xa0\xa0</li></ul><p><br></p><ul><li>The Committee considered a retrospective analysis of 16 placebo-controlled and\xa0active-controlled, and uncontrolled studies that compared safety profiles of\xa0buprenorphine transdermal patches in older patients (≥ 65 years) with younger\xa0patients (&lt; 65 years) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27929709"" target=""_blank"">Pergolizzi et al. Postgrad Med 2017;129:92-101</a>). The\xa0Committee considered that the data indicated that older patients were more likely\xa0than younger patients to experience adverse events associated with\xa0buprenorphine transdermal patches. The Committee considered that there would\xa0be value in comparative analysis of the safety of buprenorphine transdermal\xa0patches in older versus younger patients relative to other strong opioids, however\xa0the analysis presented was limited by the relatively small patient numbers.\xa0</li></ul><p><br></p><ul><li>The Committee considered a retrospective cohort study comparing rates of abuse,\xa0suspected suicidal intent and fatalities with buprenorphine transdermal patches in\xa0comparison to other opioid analgesics using data from the National Poison Data\xa0System in the US (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27922764"" target=""_blank"">Coplan PM et al. Postgrad Med 2017;129:55-61</a>). The\xa0Committee considered that the study was limited by the relatively low patient\xa0numbers prescribed buprenorphine versus other strong opioids. The Committee\xa0considered that using Poison Centre reporting may have led to under-reporting of\xa0events, and therefore considered caution was needed in interpreting the\xa0conclusion that there are lower rates of these events with buprenorphine\xa0transdermal patches in comparison to other opioid analgesics. In addition, the\xa0Committee considered that the majority of patients dispensed buprenorphine\xa0transdermal patches in the Poison Centre database used the patch concomitantly\xa0with other opioids and therefore that the use of the patch did not mean that patients\xa0would reduce their use of other opioids.\xa0</li></ul><p><br></p><ul><li>The Committee considered another retrospective cohort study from the National\xa0Poison Data System in the US evaluating buprenorphine exposure in children and\xa0adolescents (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29941678"" target=""_blank"">Post S et al. Pediatrics 2018;142:e20173562</a>). The Committee\xa0considered that this analysis included other buprenorphine formulations in addition\xa0to the transdermal patch. The Committee considered that this analysis suggested\xa0a small risk of intentional and unintentional exposure in children and adolescents\xa0that would be of potential concern if buprenorphine transdermal patches were\xa0made available in New Zealand.\xa0</li></ul><p><br></p><ul><li>The Committee considered a <a href=""https://www.cadth.ca/buprenorphine-chronic-pain-review-clinical-effectiveness-0"" target=""_blank"">rapid response document</a> prepared by the Canadian\xa0Agency for Drugs and Technology in Health (CADTH) in January 2017 that\xa0provided a summary and critical appraisal of the evidence for the clinical\xa0effectiveness of buprenorphine in chronic non-cancer pain. The Committee\xa0considered the conclusion of this review was that the improvements in pain for\xa0patients with chronic non-cancer pain, from treatment with buprenorphine relative\xa0to placebo, was modest and in some studies did not meet the recognised standard\xa0for minimum clinically important significance. The Committee considered that the\xa0authors concluded that available evidence was insufficient to assess the relative\xa0harms of buprenorphine to other opioids in patients with chronic non-cancer pain,\xa0including in relation to respiratory depression.\xa0</li></ul><p><br></p><p>The Committee considered that the evidence reviewed did not change its view that there\xa0is limited evidence of long-term analgesic benefit and functional improvements for the\xa0use of opioids, including buprenorphine transdermal patches, in the management of\xa0chronic non-malignant pain. The Committee considered that there is overwhelming\xa0evidence to suggest possible harms resulting from long term opioid use. The Committee\xa0considered that non-opioid pharmacological therapy and non-pharmacological therapies\xa0are the preferred treatment options for chronic non-malignant pain to improve functional\xa0status and health-related quality of life.\xa0\xa0</p><p><br></p><p>The Committee considered that the evidence it reviewed did not change its view that\xa0buprenorphine has a moderate abuse potential and that should buprenorphine patches\xa0be funded, there would likely be a proportion of use that would be inappropriate,\xa0including diversion and potential societal harm. The Committee considered that limiting\xa0</p><p>prescribing to certain prescriber types and patient groups would be unlikely to\xa0significantly attenuate this risk. The Committee also considered that despite\xa0buprenorphine being a transdermal patch it was possible to extract the buprenorphine\xa0from the patch.\xa0</p><p><br></p><p>The Committee considered that if buprenorphine transdermal patches were to be\xa0funded, specific advice should be sought from the Analgesic Subcommittee regarding\xa0appropriate Special Authority criteria, and that prescribing should be limited to Pain\xa0Medicine Specialists and Addiction Medicine Specialists.\xa0</p><p><br></p><p>The Committee considered that the evidence and information provided by the New\xa0Zealand Society of Anaesthetists Inpatient Pain Network did not change its view on the\xa0Analgesic Subcommittee’s recommendation that funding for buprenorphine transdermal\xa0patches be declined.\xa0</p><p><br></p><p>The Committee considered the current opioid epidemic in the US and Canada and the\xa0increasing problem of opioid prescribing for chronic non-malignant pain in New Zealand,\xa0despite large educational campaigns. The Committee considered that one possible way\xa0of reducing inappropriate prescribing of opioids for chronic non-malignant pain would be\xa0to consider funding and/or access restrictions on strong opioids. The Committee\xa0considered that similar considerations had been given to creating funding restrictions for\xa0antibiotics to help reduce antimicrobial resistance; however practically this had been\xa0difficult to implement due to significant regional variations in prescribing practice.\xa0</p>', 'Status_History__c': 'a132P000000ArgLQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3UUAQ'}, 'Id': 'a0P2P0000079y3UUAQ', 'Event_Date__c': '2022-03-08', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DatIQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p>8.24. The Committee noted an application for buprenorphine transdermal patches for severe chronic non-cancer pain that had received a recommendation for decline from PTAC in May 2019, based on insufficient evidence of long-term analgesic benefit, lack of evidence regarding functional improvements and improvements in health-related quality of life, and concerns regarding diversion and possible societal harm.</p><p><br></p><p>8.25. The Committee noted recent correspondence regarding this application received in response to recent public consultation on the decision to decline a number of funding applications. The applicant suggested that the original application was considered through a lens of conventional opioid analgesics, and that ANZCA/FPM and New Zealand Society of Anaesthetists groups have recommended use of atypical opioids before typical opioids in the setting of chronic non-cancer pain.</p><p><br></p><p>8.26. The Committee considered they had no additional comments and support PTAC’s recommendation for decline, however the Committee agreed to review further updated evidence if presented in the future.</p>', 'fs': '<p>8.24. The Committee noted an application for buprenorphine transdermal patches for severe chronic non-cancer pain that had received a recommendation for decline from PTAC in May 2019, based on insufficient evidence of long-term analgesic benefit, lack of evidence regarding functional improvements and improvements in health-related quality of life, and concerns regarding diversion and possible societal harm.</p><p><br></p><p>8.25. The Committee noted recent correspondence regarding this application received in response to recent public consultation on the decision to decline a number of funding applications. The applicant suggested that the original application was considered through a lens of conventional opioid analgesics, and that ANZCA/FPM and New Zealand Society of Anaesthetists groups have recommended use of atypical opioids before typical opioids in the setting of chronic non-cancer pain.</p><p><br></p><p>8.26. The Committee considered they had no additional comments and support PTAC’s recommendation for decline, however the Committee agreed to review further updated evidence if presented in the future.</p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf"" target=""_blank"">Meeting record</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf"" target=""_blank"">Meeting record</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Analgesic Advisory Committee at meeting Thursday 5 May 2022.', 'fs': 'Clinical advice received from Analgesic Advisory Committee at meeting Thursday 5 May 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3VUAQ'}, 'Id': 'a0P2P0000079y3VUAQ', 'Event_Date__c': '2022-08-15', 'Event_Description__c': 'Clinical advice received from Analgesic Advisory Committee at meeting Thursday 5 May 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf"" target=""_blank"">Meeting record</a></p>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Aug 2022', 'Published_Discussion__c': '<p>8.24. The Committee noted an application for buprenorphine transdermal patches for severe chronic non-cancer pain that had received a recommendation for decline from PTAC in May 2019, based on insufficient evidence of long-term analgesic benefit, lack of evidence regarding functional improvements and improvements in health-related quality of life, and concerns regarding diversion and possible societal harm.</p><p><br></p><p>8.25. The Committee noted recent correspondence regarding this application received in response to recent public consultation on the decision to decline a number of funding applications. The applicant suggested that the original application was considered through a lens of conventional opioid analgesics, and that ANZCA/FPM and New Zealand Society of Anaesthetists groups have recommended use of atypical opioids before typical opioids in the setting of chronic non-cancer pain.</p><p><br></p><p>8.26. The Committee considered they had no additional comments and support PTAC’s recommendation for decline, however the Committee agreed to review further updated evidence if presented in the future.</p>', 'Status_History__c': 'a132P000000EDDNQA4'}, 'change': None}]",Sep 2008,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2009', 'fs': 'May 2009', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3GUAQ'}, 'Id': 'a0P2P0000079y3GUAQ', 'Event_Date__c': '2009-05-10', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2009', 'Status_History__c': 'a132P000000ApQzQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3WUAQ'}, 'Id': 'a0P2P0000079y3WUAQ', 'Event_Date__c': '2022-09-30', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000EDZnQAO'}, 'change': None}]",May 2009,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2010', 'fs': 'Mar 2010', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3HUAQ'}, 'Id': 'a0P2P0000079y3HUAQ', 'Event_Date__c': '2010-03-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2010', 'Status_History__c': 'a132P000000ApYDQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2010', 'fs': 'Dec 2010', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3IUAQ'}, 'Id': 'a0P2P0000079y3IUAQ', 'Event_Date__c': '2010-12-10', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2010', 'Status_History__c': 'a132P000000AphjQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2012', 'fs': 'Sep 2012', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3JUAQ'}, 'Id': 'a0P2P0000079y3JUAQ', 'Event_Date__c': '2012-09-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2012', 'Status_History__c': 'a132P000000Aq8JQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3KUAQ'}, 'Id': 'a0P2P0000079y3KUAQ', 'Event_Date__c': '2015-03-30', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqtrQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2017', 'fs': 'Sep 2017', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3LUAQ'}, 'Id': 'a0P2P0000079y3LUAQ', 'Event_Date__c': '2017-09-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2017', 'Status_History__c': 'a132P000000ArKuQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2018', 'fs': 'Dec 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3OUAQ'}, 'Id': 'a0P2P0000079y3OUAQ', 'Event_Date__c': '2018-12-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2018', 'Status_History__c': 'a132P000000ArZyQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2019', 'fs': 'Jun 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3RUAQ'}, 'Id': 'a0P2P0000079y3RUAQ', 'Event_Date__c': '2019-06-03', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2019', 'Status_History__c': 'a132P000000ArgoQAC'}, 'change': None}]",Mar 2010,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3SUAQ'}, 'Id': 'a0P2P0000079y3SUAQ', 'Event_Date__c': '2021-06-29', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CxvRQAS'}, 'change': None}]",Jun 2021,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Consultation outcome notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Consultation outcome notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000079y3TUAQ'}, 'Id': 'a0P2P0000079y3TUAQ', 'Event_Date__c': '2021-08-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Consultation outcome notification</a></p>', 'Formatted_Date__c': 'Aug 2021', 'Status_History__c': 'a132P000000D3xNQAS'}, 'change': None}]",Aug 2021,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
